Edward Fielder

Edward Fielder

Auto-generated profile, based on publicly available information

Edward Fielder

Newcastle University Biosciences Institute, Newcastle University, Newcastle upon Tyne

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 May 2022 in eLife
Verified
Journal Article
Open access
EFEdward Fielder
Edward Fielder
TWTengfei Wan
Tengfei Wan
GAGhazaleh Alimohammadiha
Ghazaleh Alimohammadiha
AIAbbas Ishaq
Abbas Ishaq
ELEvon Low
Evon Low
SMSatomi Miwa
Satomi Miwa
Cancer survivors suffer from progressive frailty, multimorbidity, and premature morbidity. We hypothesise that therapy-induced senescence and senescence progression via bystander effects are significant causes of this premature ageing phenotype. Accordingly, the study addresses the question whether a short anti-senescence intervention is able to block progression of radiation-induced frailty and disability in a pre-clinical setting. Male mice were sublethally irradiated at 5 months of age and treated (or not) with either a senolytic drug (Navitoclax or dasatinib + quercetin) for 10 days or with the senostatic metformin for 10 weeks. Follow-up was for 1 year. Treatments commencing within a month after irradiation effectively reduced frailty progression (p<0.05) and improved muscle (p<0.01) and liver (p<0.05) function as well as short-term memory (p<0.05) until advanced age with no need for repeated interventions. Senolytic interventions that started late, after radiation-induced premature frailty was manifest, still had beneficial effects on frailty (p<0.05) and short-term memory (p<0.05). Metformin was similarly effective as senolytics. At therapeutically achievable concentrations, metformin acted as a senostatic neither via inhibition of mitochondrial complex I, nor via improvement of mitophagy or mitochondrial function, but by reducing non-mitochondrial reactive oxygen species production via NADPH oxidase 4 inhibition in senescent cells. Our study suggests that the progression of adverse long-term health and quality-of-life effects of radiation exposure, as experienced by cancer survivors, might be rescued by short-term adjuvant anti-senescence interventions.

3 August 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
JWJames Wordsworth
James Wordsworth
PNP. Yde Nielsen
P. Yde Nielsen
EFE. Fielder
E. Fielder
SCS. Chandrasegaran
S. Chandrasegaran
DSDaryl Shanley
Daryl Shanley
Summary: Ageing results from the gradual loss of homeostasis, and there are currently many hypotheses for the underlying initial causes, such as molecular damage accumulation. However, few if any theories directly connect comprehensive, underlying biological mechanisms to specific age-related diseases. We recently demonstrated how a specific maintenance system impeding overactivity disorders such as cancer might undergo positive selection while still resulting in a gradual homeostatic shift toward slower metabolism. Here we connect this metabolic slowdown, via a series of unavoidable homeostatic shifts, to the hallmarks of ageing, including mitochondrial dysfunction, insulin resistance (IR), weight gain, basal inflammation, and age-related diseases such as atherosclerosis. We constructed the fuel and energy model (FEM) based on these shifts and found that ageing via metabolic slowdown could explain not only the effects of anti-ageing interventions such as rapamycin and calorie restriction, but many of the paradoxes of ageing that currently defy alternative theories.

22 July 2024 in Journal of Investigative Dermatology
Verified
Journal Article
Open access
ELEvon Low
Evon Low
LSLucy Smith
Lucy Smith
SMSatomi Miwa
Satomi Miwa
EFEdward Fielder
Edward Fielder
SPStefan Przyborski
Stefan Przyborski
TZThomas Von Zglinicki
Thomas Von Zglinicki

16 December 2021 in bioRxiv
Verified
Preprint
Open access
PDF file
EFEdward Fielder
Edward Fielder
TWTengfei Wan
Tengfei Wan
GAGhazaleh Alimohammadiha
Ghazaleh Alimohammadiha
AIAbbas Ishaq
Abbas Ishaq
ELEvon Low
Evon Low
SMSatomi Miwa
Satomi Miwa
Cancer survivors suffer from progressive frailty, multimorbidity and premature morbidity. We hypothesize that therapy-induced senescence and senescence progression via bystander effects is a significant cause of this premature ageing phenotype. Accordingly, the study addresses the question whether a short anti-senescence intervention is able to block progression of radiation-induced frailty and disability in a pre-clinical setting. Male mice were sub-lethally irradiated at 5 months of age and treated (or not) with either a senolytic drug (Navitoclax or dasatinib + quercetin) for 10 days or with the senostatic metformin for 10 weeks. Follow up was for one year. Treatments commencing within a month after irradiation effectively reduced frailty progression (p<0.05) and improved muscle (p<0.01) and liver (p<0.05) function as well as short-term memory (p<0.05) until advanced age with no need for repeated interventions. Senolytic interventions that started late, after radiation-induced premature frailty was manifest, still had beneficial effects on frailty (p<0.05) and short-term memory (p<0.05). Metformin was similarly effective as senolytics. At therapeutically achievable concentrations metformin acted as a senostatic neither via inhibition of mitochondrial complex I, nor via improvement of mitophagy or mitochondrial function, but by reducing non-mitochondrial ROS production via NOX4 inhibition in senescent cells. Our study suggests that the progression of adverse long-term health and quality-of-life effects of radiation exposure, as experienced by cancer survivors, might be rescued by short-term adjuvant anti-senescence interventions.